In vitro activity of xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis biofilms

Yaya Rukayadi, Sunghwa Han, Dongeun Yong, Jae Kwan Hwang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The formation of Candida biofilms has important clinical ramifications, because these biofilms exhibit increased resistance to conventional antifungal therapies. The aim of this study was to investigate the activity of xanthorrhizol on biofilms produced by non-C. albicans Candida (NCAC) species, including C. glabrata, C. guilliermondii, and C. parapsilosis. NCAC biofilms were generated in flat-bottom 96-well microtiter plates and quantified using the XTT (2, 3 bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl amino) carbonyl]-2H-tetrazolium hydroxide) reduction assay. The NCAC biofilms at adherent, intermediate, and mature growth phases were treated with 0.5512 μg/ml of xanthorrhizol for 24 h. The ranges of sessile minimum inhibitory concentrations (SMICs) of xanthorrhizol against C. glabrata, C. guilliermondii, and C. parapsilosis biofilms were 832 μg/ml, 816 μg/ml, and 864 μg/ml, respectively. Xanthorrhizol affected cell density that had an indirect effect on the biofilm OD490. The compound eradicated the viable cells of the C. glabrata and C. parapsilosis biofilms at the adherent growth phase at 16 μg/ml and that of C. guilliermondii at 8 μg/ml. Treatment with 128 μg/ml of xanthorrhizol reduced the OD490 of C. glabrata, C. guilliermondii, and C. parapsilosis biofilms at the mature growth phase by 77.8%, 88.5%, and 64.5%, respectively. These results indicate that xanthorrhizol exhibits potent activity against NCAC biofilms in vitro. Therefore, xanthorrhizol has potential therapeutic value in treating biofilm-associated NCAC infections and should be further evaluated in vivo.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalMedical mycology
Volume49
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Candida glabrata
Biofilms
Candida albicans
In Vitro Techniques
xanthorrhizol
Growth
Microbial Sensitivity Tests
Candida
Cell Count

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

@article{b7d9b17672be45db898e1eecaef6e530,
title = "In vitro activity of xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis biofilms",
abstract = "The formation of Candida biofilms has important clinical ramifications, because these biofilms exhibit increased resistance to conventional antifungal therapies. The aim of this study was to investigate the activity of xanthorrhizol on biofilms produced by non-C. albicans Candida (NCAC) species, including C. glabrata, C. guilliermondii, and C. parapsilosis. NCAC biofilms were generated in flat-bottom 96-well microtiter plates and quantified using the XTT (2, 3 bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl amino) carbonyl]-2H-tetrazolium hydroxide) reduction assay. The NCAC biofilms at adherent, intermediate, and mature growth phases were treated with 0.5512 μg/ml of xanthorrhizol for 24 h. The ranges of sessile minimum inhibitory concentrations (SMICs) of xanthorrhizol against C. glabrata, C. guilliermondii, and C. parapsilosis biofilms were 832 μg/ml, 816 μg/ml, and 864 μg/ml, respectively. Xanthorrhizol affected cell density that had an indirect effect on the biofilm OD490. The compound eradicated the viable cells of the C. glabrata and C. parapsilosis biofilms at the adherent growth phase at 16 μg/ml and that of C. guilliermondii at 8 μg/ml. Treatment with 128 μg/ml of xanthorrhizol reduced the OD490 of C. glabrata, C. guilliermondii, and C. parapsilosis biofilms at the mature growth phase by 77.8{\%}, 88.5{\%}, and 64.5{\%}, respectively. These results indicate that xanthorrhizol exhibits potent activity against NCAC biofilms in vitro. Therefore, xanthorrhizol has potential therapeutic value in treating biofilm-associated NCAC infections and should be further evaluated in vivo.",
author = "Yaya Rukayadi and Sunghwa Han and Dongeun Yong and Hwang, {Jae Kwan}",
year = "2010",
month = "1",
day = "1",
doi = "10.3109/13693786.2010.492482",
language = "English",
volume = "49",
pages = "1--9",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "1",

}

In vitro activity of xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis biofilms. / Rukayadi, Yaya; Han, Sunghwa; Yong, Dongeun; Hwang, Jae Kwan.

In: Medical mycology, Vol. 49, No. 1, 01.01.2010, p. 1-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro activity of xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis biofilms

AU - Rukayadi, Yaya

AU - Han, Sunghwa

AU - Yong, Dongeun

AU - Hwang, Jae Kwan

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The formation of Candida biofilms has important clinical ramifications, because these biofilms exhibit increased resistance to conventional antifungal therapies. The aim of this study was to investigate the activity of xanthorrhizol on biofilms produced by non-C. albicans Candida (NCAC) species, including C. glabrata, C. guilliermondii, and C. parapsilosis. NCAC biofilms were generated in flat-bottom 96-well microtiter plates and quantified using the XTT (2, 3 bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl amino) carbonyl]-2H-tetrazolium hydroxide) reduction assay. The NCAC biofilms at adherent, intermediate, and mature growth phases were treated with 0.5512 μg/ml of xanthorrhizol for 24 h. The ranges of sessile minimum inhibitory concentrations (SMICs) of xanthorrhizol against C. glabrata, C. guilliermondii, and C. parapsilosis biofilms were 832 μg/ml, 816 μg/ml, and 864 μg/ml, respectively. Xanthorrhizol affected cell density that had an indirect effect on the biofilm OD490. The compound eradicated the viable cells of the C. glabrata and C. parapsilosis biofilms at the adherent growth phase at 16 μg/ml and that of C. guilliermondii at 8 μg/ml. Treatment with 128 μg/ml of xanthorrhizol reduced the OD490 of C. glabrata, C. guilliermondii, and C. parapsilosis biofilms at the mature growth phase by 77.8%, 88.5%, and 64.5%, respectively. These results indicate that xanthorrhizol exhibits potent activity against NCAC biofilms in vitro. Therefore, xanthorrhizol has potential therapeutic value in treating biofilm-associated NCAC infections and should be further evaluated in vivo.

AB - The formation of Candida biofilms has important clinical ramifications, because these biofilms exhibit increased resistance to conventional antifungal therapies. The aim of this study was to investigate the activity of xanthorrhizol on biofilms produced by non-C. albicans Candida (NCAC) species, including C. glabrata, C. guilliermondii, and C. parapsilosis. NCAC biofilms were generated in flat-bottom 96-well microtiter plates and quantified using the XTT (2, 3 bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl amino) carbonyl]-2H-tetrazolium hydroxide) reduction assay. The NCAC biofilms at adherent, intermediate, and mature growth phases were treated with 0.5512 μg/ml of xanthorrhizol for 24 h. The ranges of sessile minimum inhibitory concentrations (SMICs) of xanthorrhizol against C. glabrata, C. guilliermondii, and C. parapsilosis biofilms were 832 μg/ml, 816 μg/ml, and 864 μg/ml, respectively. Xanthorrhizol affected cell density that had an indirect effect on the biofilm OD490. The compound eradicated the viable cells of the C. glabrata and C. parapsilosis biofilms at the adherent growth phase at 16 μg/ml and that of C. guilliermondii at 8 μg/ml. Treatment with 128 μg/ml of xanthorrhizol reduced the OD490 of C. glabrata, C. guilliermondii, and C. parapsilosis biofilms at the mature growth phase by 77.8%, 88.5%, and 64.5%, respectively. These results indicate that xanthorrhizol exhibits potent activity against NCAC biofilms in vitro. Therefore, xanthorrhizol has potential therapeutic value in treating biofilm-associated NCAC infections and should be further evaluated in vivo.

UR - http://www.scopus.com/inward/record.url?scp=78650363934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650363934&partnerID=8YFLogxK

U2 - 10.3109/13693786.2010.492482

DO - 10.3109/13693786.2010.492482

M3 - Article

C2 - 20560862

AN - SCOPUS:78650363934

VL - 49

SP - 1

EP - 9

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 1

ER -